Skip to Content

Lixivaptan Approval Status

Lixivaptan is an investigational selective vasopressin 2 receptor antagonist for the treatment of symptomatic hypervolemic and euvolemic hyponatremia.

In November 2012, Cornerstone Therapeutics Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for lixivaptan had not been approved.

Development Status and FDA Approval Process for lixivaptan

Nov  1, 2012Cornerstone Therapeutics Receives Complete Response Letter From the FDA for Lixivaptan
Sep 13, 2012Cornerstone Therapeutics Provides Update on FDA Advisory Committee Discussion of Lixivaptan

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.